Literature DB >> 16012053

Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.

Riku Das1, Subha Philip, Ganapati H Mahabeleshwar, Anuradha Bulbule, Gopal C Kundu.   

Abstract

Cancer progression depends on an accumulation of metastasis supporting cell signaling molecules that target signal transduction pathways and ultimately gene expression. Osteopontin (OPN) is one such chemokine like metastasis gene which plays a key signaling event in regulating the oncogenic potential of various cancers by controlling cell motility, invasiveness and tumor growth. We have reported that OPN stimulates tumor growth and nuclear factor kappaB (NFkappaB)-mediated promatrix metalloproteinase-2 (pro-MMP-2) activation through IkappaBalpha/IKK (IkappaBalpha kinase) signaling pathway in melanoma cells. Urokinase type plasminogen activator (uPA), a widely acting serine protease degrades the ECM components and plays a pivotal role in cancer progression. However, the molecular mechanism by which upstream kinases regulate the OPN-induced NFkappaB activation and uPA secretion in human breast cancer cells is not well defined. Here we report that OPN induces the phosphatidylinositol 3'-kinase (PI 3'-kinase) activity and phosphorylation of Akt/PKB (protein kinase B) in highly invasive (MDA-MB-231) and low invasive (MCF-7) breast cancer cells. The OPN-induced Akt phosphorylation was inhibited when cells were transfected with dominant negative mutant of p85 domain of PI 3'-kinase (Deltap85) indicating that PI 3'-kinase is involved in Akt phosphorylation. OPN enhances the interaction between IkappaBalpha kinase (IKK) and phosphorylated Akt. OPN also induces NFkappaB activation through phosphorylation and degradation of IkappaBalpha by inducing the IKK activity. OPN also enhances uPA secretion, cell motility and ECM-invasion. Furthermore, cells transfected with Deltap85 or super-repressor form of IkappaBalpha suppressed the OPN-induced uPA secretion and cell motility. Pretreatment of cells with PI 3'-kinase inhibitors or NFkappaB inhibitory peptide (SN50) reduced the OPN-induced uPA secretion, cell motility and ECM-invasion. Taken together, OPN induces NFkappaB activity and uPA secretion by activating PI 3'-kinase/Akt/IKK-mediated signaling pathways and further demonstrates a functional molecular link between OPN induced PI 3'-kinase dependent Akt phosphorylation and NFkappaB-mediated uPA secretion, and all of these ultimately control the motility and invasiveness of breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012053     DOI: 10.1080/15216540500159424

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  35 in total

Review 1.  Intracellular osteopontin (iOPN) and immunity.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

2.  Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: detection by oligonucleotide microarray and real-time PCR analysis.

Authors:  Holger G Hass; Oliver Nehls; Juergen Jobst; Andrea Frilling; Ulrich Vogel; Stephan Kaiser
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

3.  Angiotensin 1-7, but not the thrombin-cleaved osteopontin C-terminal fragment, attenuates osteopontin-mediated macrophage-induced endothelial-cell inflammation.

Authors:  Rachel Hamias; Assaf Rudich; George Greenberg; Gabriel Szendro; Talya Wolak
Journal:  Inflamm Res       Date:  2017-11-27       Impact factor: 4.575

4.  The elevated expression of osteopontin and NF-κB in human aortic aneurysms and its implication.

Authors:  Tao Mi; Bin Nie; Cuntai Zhang; Honglian Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

5.  Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.

Authors:  Chandra M V Goparaju; Harvey I Pass; Justin D Blasberg; Nathalie Hirsch; Jessica S Donington
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

6.  The role of osteopontin expression in melanoma progression.

Authors:  Timea Kiss; Szilvia Ecsedi; Laura Vizkeleti; Viktoria Koroknai; Gabriella Emri; Nora Kovács; Roza Adany; Margit Balazs
Journal:  Tumour Biol       Date:  2015-05-07

7.  Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.

Authors:  Justin D Blasberg; Harvey I Pass; Chandra M Goparaju; Raja M Flores; Suzie Lee; Jessica S Donington
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

8.  RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells.

Authors:  Zhiyong Mi; Hongtao Guo; M Benjamin Russell; Yingmiao Liu; Bruce A Sullenger; Paul C Kuo
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

9.  Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappaB.

Authors:  Ida Grotterød; Gunhild M Maelandsmo; Kjetil Boye
Journal:  BMC Cancer       Date:  2010-05-28       Impact factor: 4.430

Review 10.  Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.